Quest Diagnostics Adds Diabetic Retinopathy Screening Through its Patient Service Centers in Collaboration with IRIS
SECAUCUS, N.J., April 4, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a collaboration with IRIS (Intelligent Retinal Imaging Systems) to deliver diabetic retinal imaging services through designated Quest Diagnostics patient service centers across the United States to aid in screening patients for retinal assessment by a healthcare provider. The collaboration aims to increase convenience and improve screening rates for diabetic retinopathy, the leading cause of blindness in the United Statesi, for members of population health management programs sponsored by health plans.
- In 2018, Quest Diagnostics, through its Quest HealthConnect (QHC) business, began to provide diabetic retinal imaging for use in screening using the IRIS platform.
- The new collaboration with IRIS extends the use of the IRIS platform at Quest's patient service centers.
- The new service expands on the Quest Diagnostics Extended Care portfolio of services designed to facilitate access to care beyond traditional healthcare settings.
- With training developed by IRIS, designated personnel at Quest patient service centers will transmit a patient's retinal image to a credentialed, licensed ophthalmologist to interpret the images.